Embedded Files
Tier II: The Antagonistic Hallmarks (Adaptive/Reactive Responses)
Tier II: The Antagonistic Hallmarks (Adaptive/Reactive Responses)
These mechanisms are the body's responses to the Tier 1 damage, which unfortunately become destructive themselves, driving vicious cycles of decline and contributing significantly to the physical reality of aging.
Disabled Macroautophagy
This is the failure of the cell's crucial internal "recycling" or cleaning system known as autophagy (literally, "self-eating") that breaks down and reuses damaged organelles, misfolded proteins, and pathogens. With age, the efficiency of macroautophagy declines, allowing dysfunctional mitochondria and toxic protein aggregates to accumulate, which in turn feeds the flames of chronic inflammation and cellular dysfunction. This failure directly prevents the cell from maintaining quality control and refreshing its components.
Image courtesy of: AMSBIO. (n.d.). [Illustration of the autophagy process] [Image]. https://www.amsbio.com/autophagy/
This hallmark is targeted by pharmaceuticals like Rapamycin, Metformin, Spermidine, Trehalose, and SGLT2 inhibitors (many of which inhibit the mTOR pathway elaborated later), all of which help activate the cellular cleaning process by signaling nutrient deprivation. Farthest progress is centered on designing next-generation, non-immunosuppressive mTOR inhibitors that specifically target the complex to enhance autophagy without suppressing the immune system. This allows for long-term, safe use of these compounds to promote constant cellular cleanup.
Novartis and the University of Texas Health Science Center at San Antonio (UT Health), particularly the lab of Dr. Randy Strong, have been instrumental in this research. A major breakthrough comes from the development of Rapa-analogs (rapalogues) like everolimus, which are being clinically tested to achieve the anti-aging benefits of Rapamycin with fewer side effects. Additionally, companies are focused on autophagy enhancers like Spermidine or Trehalose analogs, compounds which have been shown to induce robust autophagy and extend lifespan in multiple animal models, moving the fundamental science of cellular recycling into human clinical trials.
Kaushik, S., & Cuervo, A. M. (2015). Proteostasis and aging. Nature Medicine, 21(12), 1406–1415. https://doi.org/10.1038/nm.4001
Labbadia, J., & Morimoto, R. I. (2015). The biology of proteostasis in aging and disease. Annual Review of Biochemistry, 84, 435–464. https://doi.org/10.1146/annurev-biochem-060614-033955
Durieux, J., Wolff, S., & Dillin, A. (2011). The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell, 144(1), 79–91. https://doi.org/10.1016/j.cell.2010.12.016
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008). Adapting proteostasis for disease intervention. Science, 319(5865), 916–919. https://doi.org/10.1126/science.1153835
Deregulated Nutrient Sensing
This involves the chronic imbalance of key signaling pathways (mTOR, AMPK, Insulin/IGF-1) that detect available energy and nutrients. The mTOR pathway drives growth and proliferation when nutrients are abundant. However, its chronic activation inhibits pro-longevity stress responses, trapping the body in a permanent 'growth' mode at the expense of necessary repair. Conversely, the Insulin/IGF-1 signaling pathway also promotes cell growth and nutrient storage in response to circulating hormones. It is the AMPK pathway that acts as the counter-regulator to these growth signals. Functioning as the cell's energy sensor, AMPK activates maintenance and repair processes when energy is scarce. When this system fails and the metabolic balance shifts permanently toward growth (mTOR) rather than repair (AMPK), it leads to the metabolic diseases of aging.
IImage courtesy of: Alcock, J. (2013, September 28). October 2 No writing assignment [Blog post]. Evolution Medicine. http://evolutionmedicine.com/2013/09/28/october-2-no-writing-assignment/
Interventions include lifestyle practices like intermittent fasting and a growing pharmacopeia of geroprotectors designed to restore a balanced signaling state. This list now extends beyond Metformin and Rapamycin to include SGLT2 inhibitors (which mimic fasting by excreting glucose in the urine), Acarbose (which blocks starch digestion), and GLP-1 agonists (which regulate insulin sensitivity). Extensive data confirms that these agents can reduce the incidence of age-related disease by directly returning this sensing network. Spearheading the clinical validation of this approach is the multi-site, multi-year TAME (Targeting Aging with Metformin) trial, led by Dr. Nir Barzilai at the Albert Einstein College of Medicine. This pivotal trial aims to prove that by modulating this single pathway with an accessible, existing drug, it is possible to postpone multiple age-related diseases (including cancer, heart disease, and cognitive decline) simultaneously. (See Appendix B for more on insulin and glucose metabolism)
The TAME trial is a landmark effort because its success would compel the FDA to recognize aging itself as a treatable indication, fundamentally altering the pharmaceutical landscape. Other labs, such as those at the Salk Institute, are developing highly selective modulators that fine-tune these pathways to enhance beneficial signals (like AMPK) without causing systemic energetic stress, offering a scientifically sound path toward metabolic longevity.
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., ... & Miller, R. A. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460(7253), 392–395. https://doi.org/10.1038/nature08221
Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., ... & Glass, D. J. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 6(268), 268ra179. https://doi.org/10.1126/scitranslmed.3009892
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016). Metformin as a tool to target aging. Cell Metabolism, 23(6), 1060–1065. https://doi.org/10.1016/j.cmet.2016.05.011
Madeo, F., Eisenberg, T., Pietrocola, F., & Kroemer, G. (2018). Spermidine in health and disease. Science, 359(6374), ean2788. https://doi.org/10.1126/science.aan2788
Mitochondrial Dysfunction
This is the failure of the cell's powerhouses to efficiently produce energy (ATP), creating a chronic cellular fuel shortage and an increased output of damaging free radicals (ROS). When mitochondria become leaky, damaged, or insufficient in number, energy-intensive processes like DNA repair and protein turnover slow down dramatically, starving the cell of the necessary fuel to combat aging. This systemic energy crisis contributes to the decline of high-energy demand tissues like the brain and muscle.
IImage courtesy of: Sultana, M. A., Hia, R. A., Akinsiku, O., & Hegde, V. (2023). Peripheral Mitochondrial Dysfunction: A Potential Contributor to the Development of Metabolic Disorders and Alzheimer’s Disease. Biology, 12(7), 1019. https://doi.org/10.3390/biology12071019
Research heavily focuses on using supplements like NAD+ precursors (NMN/NR) to boost cellular energy and information signaling, and developing enhancers of mitophagy (the selective clearing of damaged mitochondria). The farthest progress reveals strikingly divergent, tissue-specific outcomes with NAD+ precursors. Interventions are now focusing on restoring the signaling molecules (specifically NAD+) that facilitate communication between mitochondria and the nucleus, allowing the cell to efficiently coordinate quality control and biogenesis.
The lab of Dr. Johan Auwerx at EPFL has made major strides in understanding mitochondrial regulation, while the company Elysium Health is a leader in commercially developing and clinically testing NAD+ boosters. A key scientific achievement comes from Dr. David Sinclair’s lab at Harvard, demonstrating that administering NAD+ precursors to aged mice reversed muscle atrophy and inflammation, functionally restoring the muscle tissue of an aged mouse to a more youthful state. This provides robust evidence that metabolic interventions can achieve cellular rejuvenation.
Gomes, A. P., Price, N. L., Ling, A. J., Moslehi, J. J., Montgomery, M. K., Rajman, L., ... & Sinclair, D. A. (2013). Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell, 155(7), 1624–1638. https://doi.org/10.1016/j.cell.2013.11.037
Dellinger, R. W., Santos, S. R., Morris, M., Evans, M., Alminana, D., Guarente, L., & Marcotulli, E. (2017). Repeat dose NRPT increases NAD+ levels in humans safely and sustainably: A randomized, double-blind, placebo-controlled study. NPJ Aging and Mechanisms of Disease, 3(1), 17. https://doi.org/10.1038/s41514-017-0016-9
Cantó, C., Houtkooper, R. H., Pirinen, E., Doherty, M. A., Ropelle, E. R., ... & Auwerx, J. (2012). The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metabolism, 15(6), 838–847. https://doi.org/10.1016/j.cmet.2012.04.022
Cellular Senescence
These are "zombie cells"—cells that have permanently stopped dividing but refuse to die, instead persisting and releasing a toxic, inflammatory cocktail known as the SASP (Senescence-Associated Secretory Phenotype). Senescent cells accumulate in nearly all tissues with age, creating a hostile microenvironment that promotes chronic inflammation, impairs stem cell function, and encourages cancer. The SASP is a powerful, local aging factor.
Image courtesy of: Gasek, N.S., Kuchel, G.A., Kirkland, J.L. et al. Strategies for targeting senescent cells in human disease. Nat Aging 1, 870–879 (2021). https://doi.org/10.1038/s43587-021-00121-8
This is currently the most clinically prioritized target. Senolytics (drugs that selectively kill senescent cells, like Dasatinib and Quercetin) are being tested in numerous human trials for everything from Idiopathic Pulmonary Fibrosis to Osteoarthritis. The clear-out-the-trash approach of senolytics is proving to be a powerful, versatile therapy, showing success in alleviating over 40 distinct age-related conditions in preclinical models.
The Mayo Clinic’s Dr. Jan van Deursen and Dr. James Kirkland are pioneers, demonstrating that genetically clearing senescent cells from progeroid and naturally aged mice extended their healthspan and lifespan. This success led directly to the formation of the biotech company Unity Biotechnology, which is conducting clinical trials aimed at removing senescent cells from the eye and knee to treat age-related vision loss and arthritis. This direct clinical translation represents one of the most immediate and tangible scientific hopes for extending healthy human lifespan.
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., ... & van Deursen, J. M. (2011). Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature, 479(7372), 232–236. https://doi.org/10.1038/nature10600
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., ... & van Deursen, J. M. (2016). Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature, 530(7589), 184–189. https://doi.org/10.1038/nature16932
Jeon, O. H., Kim, C., Laberge, R. M., Demaria, M., Rathod, S., Vasserot, A. P., ... & Elisseeff, J. H. (2017). Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nature Medicine, 23(6), 775–781. https://doi.org/10.1038/nm.4324
Page updated
Google Sites
Report abuse